Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His tag, 100µg  

Recombinant Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His tag, 100µg

Recombinant Cynomolgus / Rhesus macaque PDL1 /CD274 / B7-H1 Protein, Phe 19 - Arg 238,  produced in human 293 cells (HEK293), His tag (MALS verified)

Synonym
recombinant cynomolgus protein PDL1, PD-L1, CD274, B7-H1, B7H1, B7-H, B7H, PDCD1L1, PDCD1LG1, ADC target

More details

PD1-C52H4-100

Availability: within 7 days

420,00 €

Background
Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

Source
Recombinant Cynomolgus / Rhesus macaque PD-L1, His Tag (PD1-C52H4) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Arg 238 (Accession # G7PSE7-1). In the region Phe 19 - Arg 238, the AA sequence of Cynomolgus and Rhesus macaque PD-L1 are homologus.
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.1 kDa. The protein migrates as 33-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity"
Joung, Kirchgatterer, Singh et al
Nat Commun (2022) 13 (1), 1606
(2) "DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma"
Starzer, Heller, Tomasich et al
J Immunother Cancer (2022) 10 (3)
(3) "Comparison of the immune activation capacities of fucoidan and laminarin extracted from Laminaria japonica"
An, Hwang, Kim et al
Int J Biol Macromol (2022)
Showing 1-3 of 19373 papers.

Citations

(1) "A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade"
Authors: Geuijen C, Tacken P, Wang LC, et al.
Journal: Nature communications 2021
Application: SPR
(2) "ANTIBODIES AGAINST PD-L1"
Authors: I Altintas, D Satijn, BE Van Den, D Verzijl
Journal: US20200239579A1 2020
Application: BLI
(3) "Novel anti-PD-1 antibodies"
Authors: X Qian, et al
Journal: US20190330348A1 2019
Application: ELISA

 

The following products could also be interesting for you: